In recent years, researchers focused their attention on mesoporous silica nanoparticles (MSNs) owing to the considerable advancements of the characterization methods, especially electron microscopy methods, which allowed for a clear visualization of the pore structure and the materials encapsulated within the pores, along with the X-ray diffraction (small angles) methods and specific surface area determination by Brunauer–Emmett–Teller (BET) technique. Mesoporous silica gained important consideration in biomedical applications thanks to its tunable pore size, high surface area, surface functionalization possibility, chemical stability, and pore nature. Specifically, the nature of the pores allows for the encapsulation and release of anti-cancer drugs into tumor tissues, which makes MSN ideal candidates as drug delivery carriers in cancer treatment. Moreover, the inner and outer surfaces of the MSN provide a platform for further functionalization approaches that could enhance the adsorption of the drug within the silica network and the selective targeting and controlled release to the desired site. Additionally, stimuli-responsive mesoporous silica systems are being used as mediators in cancer therapy, and through the release of the therapeutic agents hosted inside the pores under the action of specific triggering factors, it can selectively deliver them into tumor tissues. Another important application of the mesoporous silica nanomaterials is related to its ability to extract different hazardous species from aqueous media, some of these agents being antibiotics, pesticides, or anti-tumor agents. The purpose of this paper is to analyze the methods of MSN synthesis and related characteristics, the available surface functionalization strategies, and the most important applications of MSN in adsorption as well as release studies. Owing to the increasing antibiotic resistance, the need for developing materials for antibiotic removal from wastewaters is important and mesoporous materials already proved remarkable performances in environmental applications, including removal or even degradation of hazardous agents such as antibiotics and pesticides.

The interest in wound healing characteristics of bioactive constituents and therapeutic agents, especially natural compounds, is increasing because of their therapeutic properties, cost-effectiveness, and few adverse effects. Lately, nanocarriers as a drug delivery system have been actively investigated and applied in medical and therapeutic applications. In recent decades, researchers have investigated the incorporation of natural or synthetic substances into novel bioactive electrospun nanofibrous architectures produced by the electrospinning method for skin substitutes. Therefore, the development of nanotechnology in the area of dressings that could provide higher performance and a synergistic effect for wound healing is needed. Natural compounds with antimicrobial, antibacterial, and anti-inflammatory activity in combination with nanostructured fibers represent a future approach due to the increased wound healing process and regeneration of the lost tissue. This paper presents different approaches in producing electrospun nanofibers, highlighting the electrospinning process used in fabricating innovative wound dressings that are able to release natural and/or synthetic substances in a controlled way, thus enhancing the healing process.

Colorectal cancer (CRC) remains one of the most important causes of cancer-related mortality worldwide, underscoring the need to better understand systemic inflammatory pathways across the colorectal neoplasia spectrum. In this exploratory case–control study, we characterized plasma levels of key inflammatory mediators in healthy individuals and patients with colorectal polyps or CRC. Healthy controls (n = 10), patients with colorectal polyps (CP, n = 16), early-onset CRC (EO-CRC, n = 11), and late-onset CRC (LO-CRC, n = 51) were prospectively enrolled. Plasma levels of sTNF-R, total TNF-α, PDGF-AA, IL-17A, and IL-1β were measured by ELISA. Group comparisons used Kruskal–Wallis tests with epsilon-squared effect sizes. PDGF-AA showed the strongest differences between controls and all neoplastic groups (ε² ≥ 0.15), and these comparisons remained significant after Benjamini–Hochberg false discovery rate correction. IL-17A levels were slightly higher in EO-CRC than in LO-CRC; however, this difference did not remain significant after adjustment for multiple testing. TNF-α and IL-1β showed no significant differences across groups. Overall, this study primarily provides descriptive and hypothesis-generating evidence of differential inflammatory patterns across colorectal neoplasia, with PDGF-AA emerging as the most robust signal in this exploratory dataset. These findings do not support immediate diagnostic application and require validation in larger, prospectively recruited cohorts.

The biological complexity of sarcopenia presents a major challenge for therapeutic intervention due to the wide range of degenerative changes it induces in skeletal muscle. This study demonstrates the potential of liposomal controlled release systems to address these challenges by combining two bioactive agents with complementary actions: caffeine (CAF), encapsulated in DMPC-based liposomes, and hyaluronic acid methacrylate (HAMA), encapsulated in DOPC-based liposomes. A hybrid system was also developed to deliver both substances simultaneously, aiming to restore tissue function through combined metabolic, anti-inflammatory, and regenerative effects. The liposomes exhibited nanoscale dimensions, spherical morphology, and intact membrane structure, as confirmed by electron microscopy. DLS analysis indicated good colloidal stability and monodisperse size distribution across all formulations, with improved stability observed in the hybrid system. Drug release studies showed a time-dependent profile, with HAMA releasing rapidly and CAF releasing gradually, supporting a dual-action therapeutic approach tailored to the multifactorial pathology of sarcopenia. The biological assays, performed in an established in vitro sarcopenia model, revealed the potential of liposomes co-delivering caffeine and HAMA to mitigate oxidative stress, preserve mitochondrial function, and reduce apoptosis in H₂O₂-damaged myotubes.

Accurate diagnosis of diseases in patients is crucial, particularly in older individuals, where the focus is often placed primarily on advanced age and its associated symptoms. However, advancements in technology and research have revealed that certain diseases traditionally linked to aging can also manifest in younger populations, demonstrating similar bodily changes. One such condition is sarcopenia, a degenerative disease of skeletal muscle that arises from various pathological processes affecting the tissues. In this study, we developed a liposomal formulation based on 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), in which both nicotinamide mononucleotide (NMN) and Matrigel (Mgel) were co-encapsulated, each playing a distinct role in the management of sarcopenia. NMN is known to stimulate the increase of NAD+ levels, while Matrigel enhances the activity of satellite cells, thereby facilitating muscle fiber regeneration and stabilizing protein levels. Results from the DLS, SEM, and TEM analyses revealed significant differences attributed to the type of therapeutic agent used and the synthesis parameters. Additionally, the drug release profile underscored the complementary nature and significance of selecting the appropriate active substances for effective treatment strategies. The in vitro investigations aimed to assess the potential of DMPC lipid vesicles loaded with NMN, either alone or in combination with Matrigel, to counteract sarcopenia-associated oxidative stress and mitochondrial dysfunction. The results showed that both NMN-based formulations reduced oxidative damage, preserved mitochondrial function, and maintained cytoskeletal integrity in a hydrogen peroxide-induced model of sarcopenia. Importantly, the formulation containing both NMN and Matrigel demonstrated superior protective effects, suggesting a synergistic role of the extracellular matrix components in enhancing muscle cell resilience. These findings support the use of DMPC-based delivery systems as promising candidates for sarcopenia therapy and warrant further investigation into their mechanisms of action in preventing muscle cell degeneration.

Magnetite (Fe₃O₄) nanoparticles have been explored for biomedical applications. Their surface behavior in physiological-like environments has not been fully established. Fe₃O₄ nanoparticles obtained by chemical co-precipitation were exposed to simulated body fluid (SBF) for up to 28 days, and in vitro bioactivity was examined. Structural and surface changes were investigated using XRD, FTIR-ATR, SEM/EDS and thermal analysis, while pH and electrical conductivity measurements were used to monitor changes at the particle–solution interface. Magnetite was the main crystalline phase, and the main crystalline structure was preserved during SBF exposure within the detection limits. Progressive surface transformations occurred, including hydration/hydroxylation and formation of calcium–phosphate-containing surface deposits. Changes in pH and variations in electrical conductivity were interpreted as complementary indicators of interfacial processes. Cytotoxicity tests on L929 fibroblast cells showed that Fe₃O₄_14SBF was well tolerated at 25–50 µg/mL, whereas higher concentrations reduced cell viability. These findings suggest that Fe₃O₄-based magnetic materials may be further considered for biomedical applications, provided that concentration-dependent cytocompatibility is considered.